Minute Medical

MINUTEmedical stands for Molecular, Internal radioNUclide ThErapy of the highest quality and scientific excellence. Our expert medical team, Prof.

Outpatient clinic specialized in theranostics of prostate cancer (mCRPC) & neuroendocrine tumors: Lutetium-PSMA therapy, peptide radio receptor therapy (PRRT) using somatostatin analogues, therapy of bone metastases using radium-dichloride. Welcome to MINUTEmedical - private outpatient clinic in Vienna, Austria specialized in theranostics of metastatic castration-resistant prostate cancer (mCRPC)

and neuroendocrine tumours. We offer:
• PSMA therapy with Lutetium-177 or Actinium-225,
• Peptide receptor radionuclide therapy (PRRT) using somatostatin analogues (e.g. [¹⁷⁷Lu]Lu-DOTA-TATE),
• Therapy of bone metastases using radium-223 dichloride (Xofigo®), and
• Molecular imaging ([⁶⁸Ga]Ga-PSMA-11, [⁶⁸Ga]Ga-DOTA-TATE PET-CT). Across Europe we are the only provider of these treatments in outpatient mode. Dr. Markus Hartenbach and Prof. Dr. Alexander Haug have extensive experience with these therapies: over 1000 [¹⁷⁷Lu]Lu-PSMA treatments in 8 years and over 12 years’ experience with [¹⁷⁷Lu]Lu-DOTA-TATE. Under the leadership of the prominent chemistry expert Prof. Dr. Wadzak, we produce the radiopharmaceuticals for you in our own radio-pharmacological laboratory, a so-called "hot lab". Our state-of-the-art clinic is equipped with the latest technology as demanded by the therapies we offer. We strive to provide the best care available. We thus designed the clinic so as to offer our patients the utmost in comfort, safety and discretion. All this is tailor-made to your needs and in the heart of one of the most beautiful cities in the world. Contact us for the first consultation.

07/07/2026

🇺🇸🇩🇪🇪🇸🇭🇷
🇺🇸🏆Advanced Theranostics Center of Excellence 2026. Renewed, expanded, upgraded. For the 3rd consecutive year and for the first time at Level 2. A remarkable recognition in the outpatient theranostics field ( EARL 2026). ¹⁷⁷Lu-PSMA, ¹⁶¹Tb-PSMA, ²²⁵Ac-PSMA, ¹⁷⁷Lu-DOTATATE, ²²⁵Ac-DOTATATE & ²²³Ra. Certified outpatient theranostics as a quality standard for our patients.
🇩🇪Theranostisches Kompetentzzentrum 2026. Verlängert, erweitert, upgraded. Zum 3. Mal in Folge und erstmals auf Level 2 – Advanced. Eine großartige Auszeichnung in unserem ambulanten theranostischen Bereich (EANM EARL 2026). ¹⁷⁷Lu-PSMA, ¹⁶¹Tb-PSMA, ²²⁵Ac-PSMA, ¹⁷⁷Lu-DOTATATE, ²²⁵Ac-DOTATATE & ²²³Ra. Zertifizierte ambulante Theranostik als Qualitätsstandard für unsere Patienten.
🇪🇸Centro de Excelencia Teranóstico 2026. Certificación renovada, ampliada, elevada. Por 3er año consecutivo y por primera vez en el Nivel 2 - Avanzado. Un reconocimiento extraordinario en el ámbito de la teranóstica ambulatoria (EANM EARL 2026). ¹⁷⁷Lu-PSMA, ¹⁶¹Tb-PSMA, ²²⁵Ac-PSMA, ¹⁷⁷Lu-DOTATATE, ²²⁵Ac-DOTATATE & ²²³Ra. Teranóstica ambulatoria certificada como estándar de calidad para nuestros pacientes.
🇭🇷Teranostički centar izvrsnosti 2026. Certifikacija obnovljena, proširena, unaprijeđena. Treću godinu zaredom i prvi put na Razini 2 - Advanced. Iznimno priznanje u području ambulantne teranostike (EANM EARL 2026). ¹⁷⁷Lu-PSMA, ¹⁶¹Tb-PSMA, ²²⁵Ac-PSMA, ¹⁷⁷Lu-DOTATATE, ²²⁵Ac-DOTATATE & ²²³Ra. Certificirana ambulantna teranostika kao standard kvalitete za naše pacijente.

24/06/2026

🇺🇸🇩🇪🇪🇸🇭🇷
🇺🇸Can 177Lu-PSMA damage the kidneys? A recent retrospective study of 56 patients found that kidney function remains largely stable during and after ¹⁷⁷Lu-PSMA treatment, even in patients with pre-existing kidney problems, who should be monitored more closely during treatment. Article in the profile link.

🇩🇪Kann ¹⁷⁷Lu-PSMA die Nieren schädigen? Eine aktuelle retrospektive Analyse von 56 Patienten zeigte, dass ¹⁷⁷Lu-PSMA die Nierenfunktion nicht in klinisch relevantem Ausmaß beeinträchtigt, auch bei Patienten mit bereits bestehenden Nierenproblemen, die während der Behandlung sorgfältiger überwacht werden sollten. Artikel im Profil-Link.

🇪🇸 ¿Puede ¹⁷⁷Lu-PSMA dañar los riñones? Un reciente análisis retrospectivo de 56 pacientes ha demostrado que ¹⁷⁷Lu-PSMA no pareció dañar la función renal de manera clínicamente relevante, incluso en los pacientes con problemas renales preexistentes, que deberían ser controlados más estrechamente durante el tratamiento. Artículo en el enlace del perfil.

🇭🇷 Može li ¹⁷⁷Lu-PSMA oštetiti bubrege? Retrospektivna analiza sprovedena na 56 pacijenata pokazala je da ¹⁷⁷Lu-PSMA nije doveo do klinički značajnog oštećenja bubrežne funkcije, čak i kod pacijenata sa već postojećim problemima sa bubrezima, koji zahtevaju pažljivije praćenje tokom lečenja. Članak je u linku profila.

11/06/2026

🇺🇸🇪🇸🇭🇷
🇺🇸We are opening our second facility – in . Experience the same outpatient radioligand therapy with , as well as next-generation radiopharmaceuticals and , in the modern MINUTEmedical setting. Request an initial consultation.
🇪🇸Abrimos nuestro segundo centro, ahora en . La misma terapia con radioligandos de forma ambulatoria con , así como los radiofármacos de nueva generación y , en el moderno entorno MINUTEmedical. Solicite una consulta inicial.
🇭🇷Otvaramo našu drugu lokaciju – u |u. Ista ambulantna radioligandna terapija sa Lutecijumom-177, kao i radiofarmacima nove generacije Terbijum-161 i Aktinijum-225, u savremenom MINUTEmedical dizajnu. Zakažite konsultaciju.
Cyberknife Center Salzburg

24/05/2026

🇺🇸🇩🇪🇪🇸🇭🇷
🇺🇸New evidence from the -p trial (Nature Cancer) confirms that hormone therapy rapidly boosts PSMA expression in nearly 7 in 10 patients – creating a larger target for ¹⁷⁷Lu-PSMA therapy to exploit. The result: 13.1 vs 5.8 months progression-free survival. Personalised precision oncology, available at our clinic

🇩🇪Neue Erkenntnisse aus der ENZA-p-Studie (Nature Cancer) bestätigen, dass eine Hormontherapie die PSMA-Expression bei fast 7 von 10 |patienten rasch steigert und damit ein größeres Ziel für die ¹⁷⁷Lu-PSMA-Therapie schafft. Das Ergebnis: 13,1 vs. 5,8 Monate progressionsfreies Überleben. Personalisierte Präzisionsonkologie – in unserer Klinik verfügbar.

🇪🇸Nueva evidencia del ensayo ENZA-p (Nature Cancer) confirma que la terapia hormonal aumenta rápidamente la expresión de PSMA en casi 7 de cada 10 pacientes con , creando un blanco más amplio para la terapia con ¹⁷⁷Lu-PSMA. El resultado: 13,1 vs. 5,8 meses de supervivencia libre de progresión. Oncología de precisión personalizada, disponible en nuestra clínica.

🇭🇷Novi dokazi iz ispitivanja ENZA-p (Nature Cancer) potvrđuju da hormonska terapija brzo povećava ekspresiju PSMA u gotovo 7 od 10 bolesnika s rakom prostate, stvarajući veću metu za terapiju ¹⁷⁷Lu-PSMA. Rezultat: 13,1 vs. 5,8 mjeseci preživljenja bez progresije bolesti. Personalizirana precizijska onkologija, dostupna u našoj klinici.

12/05/2026

🇩🇪PSMA-Therapie in Österreich für privatversicherte und beihilfeberechtigte Patienten aus Deutschland
🇺🇸PSMA Therapy in Austria for Patients Insured in Germany

05/05/2026

🇺🇸🇩🇪🇪🇸🇭🇷
🇺🇸BULLSEYE: 2nd study after PSMAddition confirming ¹⁷⁷Lu-PSMA in hormone-sensitive prostate cancer & 1st before ADT
58 men with oligometastatic disease: 29 treated with ¹⁷⁷Lu-PSMA and 29 on active monitoring.
Results: median +20 months without hormone therapy in the PSMA arm vs watchful waiting, 7 patients with complete biochemical remission
🇩🇪BULLSEYE: 2. Studie nach PSMAddition, die ¹⁷⁷Lu-PSMA beim hormonsensitiven Prostatakarzinom bestätigt & 1. vor Beginn der ADT
58 Männer mit oligometastatischer Erkrankung: 29 mit ¹⁷⁷Lu-PSMA behandelt, 29 unter aktiver Überwachung
Ergebnisse: median +20 Monate ohne Hormontherapie im PSMA-Arm vs. Beobachtung, 7 Patienten mit kompletter biochemischer Remission
🇪🇸BULLSEYE: 2º estudio tras PSMAddition que confirma ¹⁷⁷Lu-PSMA en el cáncer de próstata hormonosensible y 1º antes de la ADT
58 hombres con enfermedad oligometastásica: 29 tratados con ¹⁷⁷Lu-PSMA y 29 en monitorización activa
Resultados: mediana de +20 meses sin hormonoterapia en el brazo PSMA vs observación, 7 pacientes con remisión bioquímica completa
🇭🇷BULLSEYE: 2. studija nakon PSMAddition koja potvrđuje ¹⁷⁷Lu-PSMA kod hormonski osjetljivog raka prostate i 1. prije ADT
58 muškaraca s oligometastatskom bolešću: 29 liječeno ¹⁷⁷Lu-PSMA, 29 na aktivnom praćenju
Rezultati: medijan +20 mjeseci bez hormonske terapije u PSMA skupini vs promatranje, 7 bolesnika s potpunom biokemijskom remisijom

14/04/2026

Evidence from the latest clinical trials RAPID, PRIMARY2 & PROMISE supports an imaging-first pathway to prostate cancer diagnosis: PSMA PET as a triage and risk stratification tool. Read in detail here 🇺🇸🇩🇪🇪🇸🇭🇷 → https://tinyurl.com/2kb654mf

18/03/2026

🇺🇸🇩🇪🇪🇸🇭🇷
🇺🇸Read our new clinical case. Personalized theranostics in occult peritoneal carcinomatosis or how a carefully selected arsenal of isotopes, based on the latest clinical findings, paved the way to complete remission pf prostate cancer. https://tinyurl.com/3jvazcpk
🇩🇪Lesen Sie unseren neuen klinischen Fall. Individualisierte Theranostik bei okkulter Peritonealkarzinose oder wie ein sorgfältig ausgewähltes Isotopen-Arsenal auf Basis der neuesten klinischen Erkenntnisse den Weg zur kompletten Remission von Prostatakarzinom ebnete.
🇪🇸Lea nuestro nuevo caso clínico. Teranóstica personalizada en la carcinomatosis peritoneal oculta o cómo un arsenal de isótopos cuidadosamente seleccionado, basado en los hallazgos clínicos más recientes, abrió el camino hacia una remisión completa de cáncer de próstata.
🇭🇷Pročitajte naš novi klinički slučaj. Personalizovana teranostika kod okultne peritonealne karcinomatoze ili kako je pažljivo odabrani arsenal izotopa, rukovođen najnovijim kliničkim saznanjima, otvorio put ka kompletnoj remisiji karcinoma prostate.
Medisynt

Adresse

Innere Stadt
1090

Telefon

+4367762545515

Webseite

http://www.minute-medical.com/

Benachrichtigungen

Lassen Sie sich von uns eine E-Mail senden und seien Sie der erste der Neuigkeiten und Aktionen von Minute Medical erfährt. Ihre E-Mail-Adresse wird nicht für andere Zwecke verwendet und Sie können sich jederzeit abmelden.